HASBROUCK HEIGHTS, N.J., May 20, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that a symposium and panel discussion devoted to progress in the development of NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), will be held at the 2010 Annual Meeting of the American Urological Association which begins May 29 in San Francisco. The symposium, entitled "Progress with NX-1207: Phase 3 Pro-Apoptotic Injectable for BPH," will be chaired by Dr. Neal Shore, a U.S. expert in prostate diseases, and will also include several other well known authorities and practitioners in the field. More information will be made available next week at the time of the meeting.

NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms for up to 6 1/2 years.

NX-1207 is a new targeted approach to the treatment of BPH. The drug is administered by a urologist in an office setting directly into the zone of the prostate where the enlargement occurs. The procedure takes only a few minutes, causes little or no pain or discomfort, and does not require anaesthesia or catheterization. Urologists in the U.S. have expressed very positive comments about NX-1207's potential to improve the care of millions of men with BPH.

BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT:  Nymox Pharmaceutical Corporation          Roy Wolvin          1-800-93NYMOX          www.nymox.com